MUMBAI, India, Sept. 22 -- Intellectual Property India has published a patent application (202647107490 A) filed by Astrazeneca Ab; and Silence Therapeutics Gmbh on September 07, 2026, for Double-Stranded Rnai Agents And Compositions For Reducing Expression Of Angiopoietin-Like 3 (angptl3) And Methods Of Use Thereof.
Inventors include Foinquinos, Ariana; Hurt-Camejo, Eva; Peng, Xiao-Rong; Morrison, Eliot; Giannakopoulos, Stavros; Dames, Sibylle; Johannssen, Timo; Bethge, Lucas; Schubert, Steffen; and Wikstrm Lindholm, Marie.
The application for the patent was published on September 18, 2026, under issue no. 38/2026.
Abstract: There are disclosed certain double-stranded RNA (dsRNA) or siRNA agents for inhibition of angiopoietin-like 3 gene expression, compositions that include angiopoietin-like 3 agents and methods of use thereof. The double-stranded RNA (dsRNA) or siRNA agents are particularly useful in the treatment or prophylaxis of cardiovascular disease and metabolic conditions as well as in the treatment of heart failure and chronic kidney disease.
Disclaimer: Curated by HT Syndication.
